Want to see IKT full AI Analyst Report?
IKT Stock Chart & Stats
$2.49
$0.06(1.71%)
At close: 4:00 PM EST
$2.49
$0.06(1.71%)
Day’s Range― - ―
52-Week Range$1.33 - $2.61
Previous CloseN/A
Volume38.02K
Average Volume (3M)607.63K
Market Cap
$230.23M
Enterprise Value$195.36M
Total Cash (Recent Filing)$159.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 16, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding139,535,900
10 Day Avg. Volume709,252
30 Day Avg. Volume607,635
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$5.58Price Target Upside124.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$333.33K
Bulls Say, Bears Say
Bulls Say
Late-Stage Clinical ProgressAdvancing a pivotal Phase 3 study across a broad international site network moves IKT-001 closer to a potential regulatory decision and commercial validation. The 505(b)(2) pathway and reported runway through topline data may support focused execution over the next several quarters.
Orphan Drug DesignationOrphan Drug Designation strengthens the development economics of IKT-001 by providing potential tax credits, user-fee exemptions, and seven years of market exclusivity if approved. These incentives can improve the program’s strategic value and help support investment in an underserved indication.
Low Financial LeverageAn effectively debt-free balance sheet limits interest obligations and reduces solvency pressure while the company funds clinical development. This gives management greater flexibility than a highly leveraged structure, although it does not eliminate the need for additional capital during ongoing losses.
Bears Say
No Commercial ScaleThe absence of meaningful revenue shows that IKT remains dependent on clinical success before it can establish a recurring commercial earnings base. Widening losses also reduce near-term earnings visibility, leaving future value dependent on regulatory progress and eventual product commercialization.
Accelerating Cash BurnRising operating cash burn increases the amount of funding required to sustain trials and corporate operations through the next milestones. Persistently negative free cash flow can shorten financial flexibility and make future capital needs more consequential if development timelines extend.
Equity Funding DependenceReliance on equity financing exposes the company to continued shareholder dilution or ownership changes as development spending continues without product revenue. Declining equity alongside persistent losses indicates that capital is being consumed, constraining long-term financial flexibility.
Inhibikase Therapeutics News
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.33 and its highest was $2.61 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $230.23M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 27 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.108 by -$0.002.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 139,535,900 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.108. Following the earnings report the stock price went down -2.041%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.58 (124.23% Upside)
$5.58 (124.23% Upside)
Blogger Sentiment
Bullish
IKT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.27%
12-Months-Change
Fundamentals
Return on Equity
-42.80%
Trailing 12-Months
Asset Growth
84.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT Stock 12 Month Forecast
Average Price Target
$5.58
▲(124.23% Upside)
Technical Analysis
Atossa Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
TScan Therapeutics
―
Ownership Overview
16.63% Insiders
5.14% Mutual Funds
65.06% Other Institutional Investors
4.63% Public Companies and
Individual Investors